Cover Image
市場調查報告書

類鼻疽- 開發中產品分析

Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 321927
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
類鼻疽- 開發中產品分析 Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 62 Pages
簡介

類鼻疽是感染棲息於土壤中的假單孢菌屬革蘭氏陰性桿菌類鼻疽伯克氏菌造成的疾病。可經由吸入、攝取、或傷口傳染這個桿菌造成動物或人類雙方感染,症狀有發燒、咳嗽、胸部疼痛、頭痛、食慾不振等。

本報告提供類鼻疽的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

類鼻疽概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/實驗室

開發中產品的概要

  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/實驗室

治療藥的開發企業

  • Bavarian Nordic A/S 14
  • Emergent BioSolutions Inc. 15
  • Evolva SA 16
  • Soligenix, Inc. 17
  • Syntiron LLC 18

治療藥的評估

  • 單獨療法產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Burkholderia pseudomallei vaccine
  • burkholderia vaccine
  • EV-035
  • GC-072
  • SGX-101
  • SGX-942
  • SGX-943
  • Small Molecules to Inhibit FtsZ Protein for Bacterial Infections
  • Small Molecules to Inhibit InhA for Infectious Diseases

最新的開發中產品資訊

開發暫停中的計劃

產品開發的里程碑

  • 關注的新聞及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8127IDB

Summary

Global Markets Direct's, 'Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Review, H1 2016', provides an overview of the Burkholderia pseudomallei Infections (Melioidosis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkholderia pseudomallei Infections (Melioidosis) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Burkholderia pseudomallei Infections (Melioidosis)
  • The report reviews pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Burkholderia pseudomallei Infections (Melioidosis) therapeutics and enlists all their major and minor projects
  • The report assesses Burkholderia pseudomallei Infections (Melioidosis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Burkholderia pseudomallei Infections (Melioidosis)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Burkholderia pseudomallei Infections (Melioidosis)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Burkholderia pseudomallei Infections (Melioidosis) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Burkholderia pseudomallei Infections (Melioidosis) Overview
    • Therapeutics Development
  • Pipeline Products for Burkholderia pseudomallei Infections (Melioidosis) - Overview
  • Pipeline Products for Burkholderia pseudomallei Infections (Melioidosis) - Comparative Analysis
  • Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics under Development by Companies
  • Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics under Investigation by Universities/Institutes
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline Products Glance
    • Early Stage Products
  • Burkholderia pseudomallei Infections (Melioidosis) - Products under Development by Companies
  • Burkholderia pseudomallei Infections (Melioidosis) - Products under Investigation by Universities/Institutes
  • Burkholderia pseudomallei Infections (Melioidosis) - Companies Involved in Therapeutics Development
    • Bavarian Nordic A/S
    • Emergent BioSolutions Inc.
    • Grifols, S.A.
    • Soligenix, Inc.
    • Syntiron LLC
  • Burkholderia pseudomallei Infections (Melioidosis) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ARD-3100 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ARD-3150 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Burkholderia pseudomallei vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Burkholderia vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dusquetide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EV-035 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GC-072 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • melioidosis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SGX-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SGX-943 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Burkholderia pseudomallei Infections (Melioidosis) - Recent Pipeline Updates
  • Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects
  • Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products
  • Burkholderia pseudomallei Infections (Melioidosis) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
      • Aug 14, 2014: US DTRA to fund preclinical work on Evolva's antibiotic GC-072
      • Feb 21, 2014: Bavarian Nordic's MVA-BN Vaccine Platform Selected By U.S. Department Of Defense For New Vaccine Development
      • Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis), H1 2016
  • Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Bavarian Nordic A/S, H1 2016
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Emergent BioSolutions Inc., H1 2016
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Grifols, S.A., H1 2016
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Soligenix, Inc., H1 2016
  • Burkholderia pseudomallei Infections (Melioidosis) - Pipeline by Syntiron LLC, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Burkholderia pseudomallei Infections (Melioidosis) Therapeutics - Recent Pipeline Updates, H1 2016
  • Burkholderia pseudomallei Infections (Melioidosis) - Dormant Projects, H1 2016
  • Burkholderia pseudomallei Infections (Melioidosis) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Burkholderia pseudomallei Infections (Melioidosis) - Comparative Analysis, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top